Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma

被引:0
作者
C. Shu
Q. Wang
X. Yan
J. Wang
机构
[1] Nankai University,School of Medicine
[2] Tianjin Huan Hu Hospital,Tianjin Cerebral Vascular and Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute
来源
Clinical and Translational Oncology | 2018年 / 20卷
关键词
Pediatric ependymoma; CD44; Survival; miRNA; Prognostic biomarker;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1439 / 1447
页数:8
相关论文
共 115 条
[1]  
de Bont JM(2007)Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis J Neuropathol Exp Neurol 66 505-516
[2]  
den Boer ML(2017)Current therapy and the evolving molecular landscape of paediatric ependymoma Eur J Cancer 70 34-41
[3]  
Kros JM(2011)Molecular genetics of ependymoma Chin J Cancer 30 669-681
[4]  
Passier MM(2018)Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling Nature 553 101-105
[5]  
Reddingius RE(2004)The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients Cancer 100 1230-1237
[6]  
Smitt PA(2008)The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors Mod Pathol 21 165-177
[7]  
Khatua S(2011)Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts J Negat Results Biomed. 10 7-157
[8]  
Ramaswamy V(2011)Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma Cancer Cell 20 143-197
[9]  
Bouffet E(2013)Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression J Neurooncol 112 191-6460
[10]  
Yao Y(2013)PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival Clin Cancer Res 19 6450-297